This discovery not only advances our understanding of the molecular mechanisms underlying HCC progression but also provides a mechanistic foundation for novel therapeutic strategies targeting the UBE2V1–HIF-1α axis. Here, UBE2V1 is linked to hepatocellular carcinoma.